Then, the clinical outcome was detected in 70% of cases, where about 42% of cases with FLT3-wt and 71% with mutated FLT3 exhibited a clinical outcome, illustrating the anti-leukemic activity of Midostaurin in acute myeloid leukemia cases, specifically those with mutated FLT3 [59]. The gene discussed is FLT3; the disease is acute myeloid leukemia.